July 25, 2005 New Haven, Conn. -- High expression of TRAIL-R2, a cell surface receptor that triggers cell death, has been shown to be associated with a decrease the survival rates of breast cancer patients according to a study published by Yale Cancer Center researchers in Clinical Cancer Research.
Analyzing 20-year follow-up data from breast cancer patients, using an automated quantitative analysis system (AQUA
Yale Researchers concluded that while TRAIL-R1 expression was not associated with survival, high TRAIL-R2 expression strongly correlated with decreased survival.
"A number of TRAIL receptor targeting therapies are currently in clinical development. As with other targeted therapies, it is important to determine which patients are more likely to respond to these therapies," said Harriet Kluger, MD, author on the study and Assistant Professor of Medicine in the Section of Medical Oncology at Yale School of Medicine. "AQUA
Co-authors of the study include Mary M. McCarthy, and Mario Sznol, and Kyle A. DiVito, Robert L. Camp, and David L. Rimm.
The study was funded by the Susan G. Komen Foundation, the Breast Cancer Alliance and the C.J. Swebilius Foundation for Translational Research.
Citation: Clinical Cancer Research 2005;11(14) July 15, 2005
Other social bookmarking and sharing tools:
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.